AI assistant
Aclaris Therapeutics, Inc. — Director's Dealing 2016
Dec 19, 2016
33670_dirs_2016-12-19_db94b461-adf5-4826-973d-cafb2153cee6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2016-12-15
Reporting Person: Powala Christopher (Chief Operating Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-15 | Stock option (right to buy) | $28.92 | A | 62400 | Acquired | 2026-12-14 | Common Stock (62400) | Direct |
| 2016-12-15 | Restricted stock units | $ | A | 10400 | Acquired | Common Stock (10400) | Direct |
Footnotes
F1: The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F3: Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone.